Latest Report Asthma Therapeutics Market to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

Meager as the growth may look, it is important to note that the asthma therapeutics market is on the verge of witnessing widespread generic erosion. Patent expirations are expected to eat into the revenues of blockbuster drugs such as Advair (fluticasone propionate/salmeterol xinafoate), Xolair (omalizumab), and Symbicort (budesonide/formoterol fumarate). This sea change in the global asthma therapeutics market will be brought about by the entry of new players as well as the growing pervasiveness of asthma itself.

Browse Full Report with TOC : http://www.mrrse.com/asthma-therapeutics-market

The report notes that there is unparalleled industry interest in monoclonal antibodies and biologics, with the former enjoying more attention within the indication. Clinical trials have shown encouraging results for new monoclonal antibodies; some of these include: Lebrikizumab, mepolizumab, dupilumab target Interleukins (IL), and reslizumab. 

These molecules are seen to be beneficial in inadequately controlled or severe eosinophilic asthma. 

These drugs, which will constitute a sizeable chunk of the personalized asthma therapeutics market, will target a small section of asthma patients, but will carry steep price tags and still drive market growth. This, market experts predict, will ostensibly offset the detrimental effects of generic erosion.

Healthcare systems worldwide are already heaving the burden of growing incidences of asthma, show figures from the World Health Organization.

 The disease—which affected an estimated 300 million people worldwide in 2007—is projected to spread to 400 million people by 2025. While the better part of asthma patients are able to bring their symptoms under control using products currently available on the market, there is still a considerable chunk of asthma victims that cannot do so. 

This unmet need in the global asthma therapeutics market has kindled the interest of pharmaceutical companies and other industry players.

This has proven highly beneficial to the current asthma pipeline, with several promising molecules reported to be on the anvil. A number of these molecules are in the later stages of development and are expected to hit the asthma therapeutics market as early as 2015-16.

Send An Enquiry: http://www.mrrse.com/enquiry/106

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

 2 Introduction

2.1 Disease Introduction

2.2 Epidemiology

2.3 Etiology

2.4 Pathophysiology

2.5 Symptoms

2.6 Diagnosis

2.7 Assessment of Disease Severity

2.8 Treatment

2.9 Treatment Algorithm

2.10 Treatment Segments

2.10.1 ICS Monotherapy for the Maintenance Treatment of Asthma

2.10.2 Singulair (montelukast sodium) as First-Line Maintenance Therapy

2.10.3 ICS/LABA Combination Therapy

2.10.4 Add-on Therapies

 3 Marketed Products

3.1 Overview

3.2 ICS for the Maintenance Treatment of Asthma

3.2.1 Arnuity (fluticasone furoate) – GSK

3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma

3.3.1 Advair (fluticasone propionate and salmeterol xinafoate) – GSK

3.3.2 Symbicort (budesonide and formoterol fumarate) – AstraZeneca, Co-Promotion with Astellas Pharma

3.3.3 Dulera (mometasone furoate and formoterol fumarate) – Merck

3.3.4 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) – GlaxoSmithKline/Theravance

3.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma

3.4.1 Xolair (omalizumab) – Novartis and Genentech

3.4.2 Singulair (montelukast) – Merck

3.4.3 Spiriva (tiotropium bromide) – Boehringer Ingelheim

3.5 Heat Maps for Marketed Products

 4 Asthma Pipeline

4.1 Overview

4.2 Pipeline Analysis by Stage of Development, Molecule Type and Program Type

4.3 Pipeline Analysis by Molecular Target

4.4 Asthma Clinical Trial Landscape

4.4.1 Clinical Trial Failure Rates

4.4.2 Clinical Trial Duration

4.4.3 Clinical Trial Size

4.4.4 Comparative Clinical Trial Metrics Analysis

4.5 Promising Pipeline Molecules

4.5.1 Mepolizumab – GSK

4.5.2 Reslizumab – Teva Pharmaceutical

4.5.3 Lebrikizumab – Roche/Genentech

4.5.4 Dupilumab – Regeneron Pharmaceuticals in Collaboration with Sanofi

4.5.5 Masitinib – AB Science

4.6 Heat Map and Competitor Matrix for Pipeline Products

 5 Market Forecast to 2020

5.1 Geographical Markets

5.2 Global Market

5.3 North America

5.3.1 Treatment Usage Patterns

5.3.2 Annual Cost of Therapy

5.3.3 Market Size

5.4 Top Five Countries of Europe

5.4.1 Treatment Usage Patterns

5.4.2 Annual Cost of Therapy

5.4.3 Market Size

5.5 Japan

5.5.1 Treatment Usage Patterns

5.5.2 Annual Cost of Therapy

5.5.3 Market Size

5.6 Drivers and Barriers for the Asthma Market

5.6.1 Drivers

5.6.2 Barriers

 6 Strategic Consolidations

6.1 Co-development Deals

6.1.1 Sepracor Enters into Co-Development Agreement with Nycomed for Ciclesonide

6.1.2 NeoStem Enters into Agreement with University of California to Develop Human Regulatory T Cells

6.1.3 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies

6.2 Licensing Deals

6.2.1 Amgen Enters into Licensing Agreement with Kyowa Hakko Kirin – Terminated

6.2.2 Mundipharma Enters into Licensing Agreement with SkyePharma

6.2.3 MAP Pharmaceuticals Enters into Licensing Agreement with AstraZeneca – Terminated

6.2.4 Orexo Enters into Licensing Agreement with Janssen Pharmaceuticals – Terminated

6.2.5 Aslan Pharma Enters into Licensing Agreement with CSL for CSL-334

 7 Appendix

7.1 All Pipeline Drugs by Phase of Development

7.1.1 Discovery

7.1.2 Preclinical

7.1.3 Phase I

7.1.4 Phase II

7.1.5 Phase III

7.1.6 Pre-registration

7.2 Market Forecasts to 2020

7.2.1 Global

7.2.2 US

7.2.3 Canada

7.2.4 UK

7.2.5 France

7.2.6 Germany

7.2.7 Italy

7.2.8 Spain

7.2.9 Japan

7.3 References

7.4 Abbreviations

7.5 Research Methodology

7.5.1 Secondary Research

7.5.2 Marketed Product Profiles

7.5.3 Late-Stage Pipeline Candidates

7.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products

7.5.5 Product Competitiveness Framework

7.5.6 Pipeline Analysis

7.5.7 Forecasting Model

About Us:

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact

State Tower

90, State Street

Suite 700

Albany, NY - 12207

United States

Telephone: +1-518-618-1030

Email: sales@mrrse.com

Website: http://www.mrrse.com/